Experts Video Reports: Neuroendocrine Tumours track

Reporting from the ESMO Congress 2021, Rocio Garcia-Carbonero summarises the interesting results presented in the NETs track including the phase III SPINET study testing lanreotide autogel/depot in patients with advanced lung NETs, response and PFS results from the AXINET study testing axitinib plus octreotide LAR in patients with grade 1-2 extrapancreatic NETs, and the GCO-001 NIPINEC of nivolumab+ipilimumab in pre-treated patients with advanced refractory pulmonary or GEP poorly differentiated NECs, designed to explore the efficacy of immunotherapy in this setting.

Reporting from ESMO Congress 2019, Philippe Ruszniewski comments on results of 3 studies that evaluated the effects of the addition of radioembolisation to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumours (NETs), doubling a dose of lanreotide in patients with pancreatic or midgut NETs who progressed on conventional dosage, and the efficacy and safety of novel tyrosine kinase inhibitor surufatinib in well-differentiated advanced extrapancreatic NETs.

Nicola Fazio provides an overview of the current state of the art regarding the management of neuroendocrine neoplasms by reviewing tumour biology and recent novelties in diagnostic imaging methods, and concluding with the adoption of treatment novelties into clinical practice.

Chris Verslype explains that the management of gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) should rely on pathology findings on how well differentiated the tumour is, and the level of proliferation marker Ki67. He describes treatment options and follow-up plan recommendations according to disease staging.

Juan Valle explains that some patients with neuroendocrine tumours suffer from carcinoid syndrome characterised by very specific symptoms. He stressed out why it is important to detect it, and details its physiopathology, how carcinoid syndrome should be managed and what are the available treatments.